Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6579
Source ID: NCT05553093
Associated Drug: Tirzepatide
Title: Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
Acronym:
Status: RECRUITING
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Tirzepatide|DRUG: Insulin Glargine
Outcome Measures: Primary: blood sugar changes, Effects of Tirzepatide and Insulin Glargine on blood sugar changes in Patients With Type 2 Diabetes Mellitus, 40 weeks|blood lipid changes, Effects of Tirzepatide and Insulin Glargine on blood lipid changes in Patients With Type 2 Diabetes Mellitus, 40 weeks|Brain function, Effects of Tirzepatide and Insulin Glargine on brain function through VBM and ASL-fMRI in Patients With Type 2 Diabetes Mellitus., 40 weeks | Secondary: Body composition analysis, Effects of Tirzepatide and Insulin Glargine on body composition in Patients With Type 2 Diabetes Mellitus. A body composition analysis will assess the fat and muscle makeup of your body., 40 weeks|Inflammation factors, including adiponectin,leptin,IL-1,IL-6,IL-18,TNF-α,ghrelin,asprosin., Effects of Tirzepatide on inflammation factors in Patients With Type 2 Diabetes Mellitus,after being intervened for 40 weeks,changes of Inflammation factors were observed, including adiponectin,leptin,IL-1,IL-6,IL-18,TNF-α,ghrelin,asprosin., 40 weeks
Sponsor/Collaborators: Sponsor: Nanjing First Hospital, Nanjing Medical University
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 150
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2022-03-15
Completion Date: 2027-10-31
Results First Posted:
Last Update Posted: 2022-09-23
Locations: Nanjing First Hospital, Nanjing, Jiangsu, 210006, China
URL: https://clinicaltrials.gov/show/NCT05553093

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress